rbbp4 Antibody

Cancer Biology

RBBP4 overexpression correlates with poor prognosis in multiple cancers:

Neurodevelopment and Aging

• Embryogenesis: Rbbp4 knockout mice show defective inner cell mass formation, DNA damage, and apoptosis in blastocysts .

• Memory Loss: Age-related RBBP4 decline in the dentate gyrus contributes to memory deficits; restoration reverses cognitive decline in mice .

Diagnostic and Prognostic Utility

• LGG: RBBP4 expression positively correlates with immune cell infiltration (macrophages, dendritic cells) and predicts shorter survival (HR = 2.34, p < 0.05) .

• NSCLC: High RBBP4 levels associate with advanced tumor stage (p < 0.01) and resistance to autophagy-mediated cell death .

Therapeutic Targeting

• Autophagy Induction: RBBP4 knockdown in NSCLC cells activates autophagic pathways (LC3-II elevation) and inhibits tumor growth in vivo .

• Epigenetic Modulation: Dopamine agonists (e.g., 6-Br-APB) and cAMP activators rescue RBBP4-deficient memory deficits via PKA-CREB1 signaling .

Technical Considerations

• Antibody Validation:

  • Optimal dilution ranges: WB (1:500–1:6000), IHC (1:1000–1:4000) .

  • Antigen retrieval recommended for IHC (TE buffer pH 9.0 or citrate buffer pH 6.0) .

• Limitations: Cross-reactivity with RBAP46 (83% sequence homology) may require validation in species-specific models .

Future Directions

• Biomarker Development: Validate RBBP4 as a pan-cancer prognostic marker using multi-omics datasets.

• Therapeutic Strategies: Explore small-molecule inhibitors targeting RBBP4’s WD40 domain to disrupt chromatin remodeling in cancers .